{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:40:46Z","timestamp":1789926046962,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Angioedema can occur in the absence of urticaria and can be broadly divided into three main categories: mast cell-mediated (e.g., histamine), non-mast-cell-mediated (bradykinin-induced) and idiopathic angioedema. Non-mast-cell-mediated angioedema is largely driven by bradykinin. Bradykinin-induced angioedema can be hereditary, acquired or drug-induced, such as with angiotensin-converting enzyme (ACE) inhibitors. Although bradykinin-mediated angioedema can be self-limited, it can cause significant morbidity and laryngeal involvement may lead to fatal asphyxiation. The mainstays of management for angioedema are: (1) to avoid specific triggers (if possible and where known) and (2) treatment with medication (if indicated). For hereditary angioedema (HAE), there are specifically licensed treatments that can be used for the management of attacks, or for prophylaxis in order to prevent attacks. In this article, the authors will review the causes, diagnosis and management of angioedema.<\/jats:p>","DOI":"10.1186\/s13223-024-00934-3","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:47:32Z","timestamp":1733748452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Angioedema"],"prefix":"10.1186","volume":"20","author":[{"given":"Gina","family":"Lacuesta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"7","key":"934_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update. Allergy. 2022;77(7):1961\u201390.","journal-title":"Allergy"},{"issue":"3","key":"934_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, Gim\u00e9nez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticarial. A GA2LEN task force report. Allergy. 2011;66(3):317\u201330.","journal-title":"Allergy"},{"issue":"3","key":"934_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366.","journal-title":"Allergy"},{"issue":"5","key":"934_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.anai.2022.07.017","volume":"129","author":"VP Goswamy","year":"2022","unstructured":"Goswamy VP, Lee KE, McKernan EM, Fichtinger PS, Mathur SK, Viswanathan RK. Omalizumab for treatment of idiopathic angioedema. Ann Allergy Asthma Immunol. 2022;129(5):605-611.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"934_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/00325481.2021.1905364","volume":"133","author":"J Jacobs","year":"2021","unstructured":"Jacobs J, Neeno T. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency. Postgrad Med. 2021;133(6):639\u201350.","journal-title":"Postgrad Med"},{"issue":"37","key":"934_CR6","doi-asserted-by":"publisher","first-page":"E1283","DOI":"10.1503\/cmaj.220604","volume":"194","author":"I Chair","year":"2022","unstructured":"Chair I, Lacuesta G, Nash CM, Cook V. A challenging diagnosis: hereditary angioedema presenting during pregnancy. CMAJ. 2022;194(37):E1283\u20137.","journal-title":"CMAJ"},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","volume":"15","author":"S Betschel","year":"2019","unstructured":"Betschel S, Badiou J, Binkley K, Borici-Mazi R, H\u00e9bert J, Kanani A, et al. The international\/canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2019;15:72.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"934_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.iac.2006.08.002","volume":"26","author":"LC Zingale","year":"2006","unstructured":"Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am. 2006;26(4):669\u201390.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"934_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2340\/00015555-1760","volume":"94","author":"ER Rasmussen","year":"2014","unstructured":"Rasmussen ER, Mey K, Bygum A. Angiotensin-converting enzyme inhibitor-induced angioedema\u2014a dangerous new epidemic. Acta Derm Venereol. 2014;94(3):260\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"934_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.iac.2006.08.001","volume":"26","author":"JB Byrd","year":"2006","unstructured":"Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26(4):725\u201337.","journal-title":"Immunol Allergy Clin North Am"},{"key":"934_CR11","first-page":"A92","volume":"102","author":"AJ Castaldo","year":"2009","unstructured":"Castaldo AJ, Vernon MK, Lumry WR, et al. Humanistic burden of hereditary angioedema [abstract P249]. Ann Allergy Asthma Immunol. 2009;102:A92.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"934_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","volume":"31","author":"WR Lumry","year":"2010","unstructured":"Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407\u201314.","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"934_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","volume":"119","author":"K Bork","year":"2006","unstructured":"Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267\u201374.","journal-title":"Am J Med"},{"key":"934_CR14","doi-asserted-by":"crossref","unstructured":"Agostoni A, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress. Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;4(suppl):S51\u2013131.","DOI":"10.1016\/j.jaci.2004.06.047"},{"key":"934_CR15","unstructured":"Canadian Hereditary Angioedema Network. Patient resources. Available at: https:\/\/chaen-rcah.ca\/patient-resources\/ Accessed May 30, 2024."},{"key":"934_CR16","unstructured":"BioCryst Pharmaceuticals Inc. Berotralstat (Orladeyo) product monograph. June 2, 2022."},{"issue":"12","key":"934_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2146\/ajhp150482","volume":"73","author":"MJ Scalese","year":"2016","unstructured":"Scalese MJ, Reinaker TS. Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors. Am J Health Syst Pharm. 2016;73(12):873\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"934_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100621","volume":"15","author":"DH Jones","year":"2022","unstructured":"Jones DH, Bansal P, Bernstein JA, Fatteh S, Harper J, Hsu FI, et al. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organ J. 2022;15(1): 100621.","journal-title":"World Allergy Organ J"},{"issue":"Suppl 2","key":"934_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13223-018-0288-z","volume":"14","author":"A Kanani","year":"2018","unstructured":"Kanani A, Betschel SD, Warrington R. Urticaria and angioedema. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):59.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00934-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-024-00934-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00934-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:43:27Z","timestamp":1748360607000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-024-00934-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":19,"journal-issue":{"issue":"S3","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1186\/s13223-024-00934-3","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Gina Lacuesta has received consulting fees, honoraria and research funding from Takeda, AstraZeneca and Novartis; consulting fees and honoraria from CSL Behring, GSK, Sanofi, Pfizer and Amgen; and consulting fees from BioCryst. Dr. Ellie Tsai has received honoraria and consulting fees from ALK, Astra Zeneca, ICI Medical Communications, Novartis and Sanofi; honoraria from Covis Pharma, CPD Network, GSK, Medexus, Miravo Healthcare and Valeo Pharma; and consulting fees from Bausch Health. Dr. Stephen D. Betschel has received consulting fees, honoraria, and research funding from Astria, Canadian Blood Services, CSL Behring, Green Cross, Grifols, Ionis Pharmaceuticals, Kalvista Novartis, Octapharma, Pharvaris, Sanofi, Takeda, and WSIB. Dr. Harold Kim has received consulting fees from and\/or has participated in speakers\u2019 bureau and\/or advisory boards for ALK, AstraZeneca, Bausch Health, CSL Behring, GSK, Miravo, Novartis, Pediapharm, Pfizer, Sanofi, Shire, Takeda and Valeo.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}